Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Henagliflozin Add-on to Metformin in Type 2 Diabetes
NCT04390295Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Nov 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of henagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoint: Adjusted Mean Change in HbA1c Levels at 24 weeks. Status: unknown.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04390295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390295.